Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiation therapy for patients with diffuse large B cell Richter's syndrome of CLL
    Meeting Abstract

    Sacchi De Camargo Correia, G.; Imber, B. S.; Hajj, C.; Thompson, M. C.; Mato, A. R.; Yahalom, J.; Roeker, L. E.
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of entospletinib in combination with intensive induction and consolidation chemotherapy in adults with newly diagnosed nucleophosmin 1-mutated acute myeloid leukemia
    Meeting Abstract

    Byrd, J. C.; Cortes, J. E.; Minden, M. D.; Oellerich, T.; Stein, E. M.; Elder, J.; Kumar, P.; Bray, G.; DiMartino, J.; Stock, W.
    Blood (2021)

    Fulltext@MSK | Save
  • Multi-recombinase mouse models of FLT3-driven leukemia identifies distinct trajectories of mutational cooperativity and leukemic transformation
    Meeting Abstract

    Bowman, R. L.; Mishra, T.; Eisman, S. E.; Cai, L.; Xiao, W.; Waarts, M. R.; Sanchez Vela, P.; Fernández-Maestre, I.; Csete, I. S.; Potts, C. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 car NK cell therapy in relapsed/refractory B-cell lymphoma
    Meeting Abstract

    Bachanova, V.; Ghobadi, A.; Patel, K.; Park, J. H.; Flinn, I. W.; Shah, P.; Wong, C.; Bickers, C.; Szabo, P.; Wong, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Multicenter analysis of treatment and outcomes for patient with TP53 mutated AML in the era of novel therapies; Significant impact of allogeneic stem cell transplantation on survival
    Meeting Abstract

    Badar, T.; Litzow, M. R.; Shallis, R. M.; Bewersdorf, J. P.; Saliba, A.; sacchi De Camargo Correia, G.; Stahl, M.; Goldberg, A. D.; Atallah, E. L.; Foran, J. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Trial in progress: Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations
    Meeting Abstract

    Andorsky, D.; Tomassetti, S.; Deutsch, Y. E.; Broun, E. R.; Issa, G. C.; Levy, M. Y.; Deininger, M. W.; Maegawa, R.; Shrestha, A.; Mauro, M. J.
    Blood (2021)

    Fulltext@MSK | Save
  • Germline RUNX1 mutations induce inflammation in hematopoietic stem and progenitor cells and predispose to hematologic malignancies
    Meeting Abstract

    Ahmad, M. H.; Hegde, M.; Wong, W. J.; Dunbar, A.; Carrascoso, A.; Garett, L. J.; Ferreira, N. K.; Liu, H.; Li, R.; Eberg, B. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive or Ph-like acute lymphoblastic leukemia (ALL) (with dasatinib sensitive fusions/ mutations)
    Meeting Abstract

    Advani, A.; Moseley, A.; O'Dwyer, K.; Wood, B.; Park, J. H.; Wieduwilt, M.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; George, M.; Venkatesh, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on chromatin remodeling and MAPK activation and is targetable
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Stivala, S.; Brkic, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save